MACSF

COMMUNIQUÉS West-GlobeNewswire

Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®
04/06/2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, [...]
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
04/06/2025
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane [...]
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
04/06/2025
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology [...]
Aveanna Healthcare Holdings Completes Acquisition of Thrive Skilled Pediatric Care
04/06/2025
ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today [...]
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
04/06/2025
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE [...]
The Joint Corp. Appoints Sandi Karrmann as Director
04/06/2025
- Accomplished Global HR Executive with Deep Franchise and Healthcare Expertise, including CHRO Roles at Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International, to Join Board - SCOTTSDALE, Ariz., June 04, [...]
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
04/06/2025
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically [...]
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
04/06/2025
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“ [...]
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
04/06/2025
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from [...]
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
04/06/2025
Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company’s transition to a commercial-stage, revenue-generating [...]
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
04/06/2025
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from [...]
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
04/06/2025
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle [...]
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46 th Annual Global Healthcare Conference on Wednesday, [...]
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
04/06/2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to [...]
Revive Therapeutics Advances with Next-Generation Bucillamine Development
04/06/2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity
04/06/2025
BURLINGAME, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Today, Accumulus Synergy (“Accumulus”) announced a strategic partnership with Veeva Systems (“Veeva”) focused on enabling connectivity to help the life sciences [...]
Accumulus Synergy et Veeva Systems s’associent afin d’accélérer la transformation réglementaire et la connectivité
04/06/2025
BURLINGAME, Calif., 04 juin 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy (« Accumulus ») a annoncé aujourd’hui un partenariat stratégique avec Veeva Systems (« Veeva ») axé sur la mise en place de solutions de [...]
TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors
04/06/2025
- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with KRAS-G12C-mutant NSCLC, EGFR- [...]

Pages